DRUG · Unmapped registry intervention
IL-2
Find medicine records ·
Find other trials using this name
Clinical trial
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
NCT03474497
Study summary
ClinicalTrials.govUCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1, PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Pembrolizumab
Normalized identity: pembrolizumab View linked drug · Find medicine records ·
Find other trials using this name
RADIATION · Unmapped registry intervention
Radiotherapy
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Interventions
Sponsors & collaborators
Megan Daly, MDlead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03474497 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.